Latest News

Twenty-five years after September 11, Dermatology Times reflects on the burn injuries, skin conditions, and clinicians who cared for survivors.

FDA review of BOTOX Cosmetic for masseter prominence signals on-label jawline contouring, trial-backed results, clearer dosing guidance, and safer patient counseling.

Dietary modification may improve disease activity and quality of life in some patients with chronic idiopathic urticaria.

Genetic analysis finds smoking unlikely to cause urticaria, suggesting past links reflect confounding. Find out what this means for triggers and patient care.

Phase 2 SkinJect data support the 200-µg dose and inform Medicus’ FDA-authorized registrational program in Gorlin syndrome.

A 3-patient case series explored photothermal biomodulated PRP with laser and LED therapy for acne-related erythema, hyperpigmentation, and scarring.

Fractional carbon dioxide laser targets acne conglobata skin bridges and sinus tracts, delivering marked improvement, quick healing, and no recurrence.

Advanced practice providers will gather September 12 for a full-day program covering skin cancer prevention, diagnosis, staging, treatment, and procedural skills.

This review of the latest dermatological studies includes insights on AGA and cardiovascular risk, adverse events associated with cutaneous procedures, narrowband-UVB phototherapy for urticaria pigmentosa, and more.

Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.

Study tracks teens on isotretinoin, finding stable cognition but modest rises in depression and anxiety symptoms, reinforcing the need for ongoing mental health monitoring.

FDA granted QRX003 RPD designation for PSS, adding to its Netherton syndrome designation as Quoin prepares for a phase 2 study.

Real-world cohort research links psoriasis biologics to notably fewer heart attacks and strokes over 10 years, with benefits across drug classes and races.